Category Archives: Life Extension

HOUSTON, Nov. 16, 2021 /PRNewswire/ --RESA Power, LLC, a market leader in power systems electrical testing, transformer services and life extension solutions for power distribution equipment, has announced the acquisition of Priority 1 Power Services, LLC.

Based in Phoenix, AZ, Priority 1 Power Services (P1PS) has been providing electrical testing services in the Phoenix Metropolitan Area and throughout Arizona since 1993. P1PS specializes in offering electrical testing services and maintenance, troubleshooting and start-up services for Automatic Transfer Switches (ATS) and Generator Parallel Switchgear.

Mark Angus, Chief Growth Officer at RESA Power, commented on the acquisition, "We have held ambitions to expand into the Greater Phoenix area and Arizona in general for a long time, and we are delighted to team up with Glade, Brandon and the rest of the Priority 1 team. This partnership gives RESA the ideal springboard from which to grow aggressively in the fast-growing Arizona market and provides us with the perfect location to better service our customers throughout the Southwest region."

Co-owners Glade Swenson, and Brandon Carrasco, view the new partnership with RESA Power as a critical step to position Priority 1 for accelerated growth. "I'm very proud of what we've achieved at Priority 1 over almost three decades and now the time is right to team up with a partner that has the resources to help take us to the next level," said Glade Swenson, Co-owner, and original Founder. Brandon Carrasco, who will assume the role of General Manager, added "We are fortunate to have earned the trust of a very loyal customer base and we are excited to be able to offer them the expanded range of resources, services and products that RESA brings."

About RESA Power, LLC

RESA Power, a portfolio company of Blue Sea Capital, is a market leader in power systems services and life extension solutions for power distribution equipment used in mission critical environments. With locations across the United States and Canada, RESA Power is uniquely capable of ensuring our customers' critical power systems are safe, reliable, and operating at peak efficiency. The technicians and engineers at RESA are experts in testing and servicing transformers, relays, breakers and other key components of power distribution and control systems. RESA also provides quick turn-around custom manufactured or retrofit switchgear & breaker solutions and maintains an extensive inventory of obsolete and hard-to-find components. For more information about how to join the RESA Power group, visit https://www.resapower.comhttp://blueseacapital.com/

Media contact:Julia BaranavaMarketing Manager832-900-8343[emailprotected]

SOURCE RESA Power

https://www.resapower.com

Read more:

RESA Power Expands Operations into the Valley of the Sun - PRNewswire

DetailsCategory: AntibodiesPublished on Friday, 19 November 2021 07:46Hits: 289

Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic COVID-19, with no severe disease or deaths with AZD7442

Separate treatment trial showed 88% reduced risk of severe COVID-19 or death when treated within three days of symptom onset

LONDON, UK I November 18, 2021 I New data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials both showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination.

In an analysis of the ongoing PROVENT trial evaluating a median six months of participant follow-up, one 300mg IM dose of AZD7442 reduced the risk of developing symptomatic COVID-19 compared to placebo by 83%.

About 2% of theglobalpopulation is considered at increased risk of an inadequate response to a COVID-19 vaccine.1 This includes people with blood cancers or other cancers being treated with chemotherapy, patients on dialysis, those taking medications after an organ transplant or who are taking immunosuppressive drugs for conditions including multiple sclerosis and rheumatoid arthritis.2-6

The AZD7442 PROVENT trial is the first Phase III trial prospectively designed to evaluate a monoclonal antibody for pre-exposure prophylaxis of symptomatic COVID-19, with targeted inclusion of high-risk and immunocompromised participants. More than 75% of PROVENT participants at baseline had co-morbidities that put them at high risk for severe COVID-19 if they were to become infected, including people who are immunocompromised and may have a reduced immune response to vaccination.

There were no cases of severe COVID-19 or COVID-19-related deaths in those treated with AZD7442 at either the primary or six-month analyses. In the placebo arm, there were two additional cases of severe COVID-19 at the six-month assessment, for a total of five cases of severe COVID-19 and two COVID-related deaths.

An exploratory analysis of the TACKLE outpatient treatment trial, in patients with mild-to-moderate COVID-19, showed that one 600mg IM dose of AZD7442 reduced the risk of developing severe COVID-19 or death (from any cause) by 88% compared to placebo in patients who had been symptomatic for three days or less at the time of treatment.

A total of 90% of participants enrolled in TACKLE were from populations at high risk of progression to severe COVID-19 if they became infected, including those with co-morbidities.

In both PROVENT and TACKLE, AZD7442 was generally well tolerated. No new safety issues were identified in the six-month analysis of PROVENT.

Hugh Montgomery, Professor of Intensive Care Medicine at University College London, UK and AZD7442 principal investigator, said: These compelling results give me confidence that this long-acting antibody combination can provide my vulnerable patients with the long-lasting protection they urgently need to finally return to their everyday lives. Importantly, six months of protection was maintained despite the surge of the Delta variant among these high-risk participants who may not respond adequately to vaccination.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: AZD7442 is the only long-acting antibody with Phase III data to demonstrate benefit in both pre-exposure prophylaxis and treatment of COVID-19 with one dose. These new data add to the growing body of evidence supporting AZD7442s potential to make a significant difference in the prevention and treatment of COVID-19. We are progressing regulatory filings around the world and look forward to providing an important new option against SARS-CoV-2 as quickly as possible.

Full results from PROVENT and TACKLE will be submitted for publication in a peer-reviewed medical journal and presented at a forthcoming medical meeting.

On 5 October 2021, the Companyannouncedthat it had submitted a request to the US Food and Drug Administration for Emergency Use Authorisation for AZD7442 for prophylaxis of COVID-19.

AstraZeneca has agreed to supply the US Government with 700,000 doses of AZD7442 if granted an Emergency Use Authorization by the FDA, and has agreements to supply to other countries.

Notes

PROVENTPROVENT is a Phase III, randomised, double-blind, placebo-controlled, multi-centre trial assessing the safety and efficacy of a single IM 300mg dose of AZD7442 compared to placebo for the prevention of COVID-19 in participants who did not have who did not have SARS-CoV-2 infection at baseline. The trial was conducted in 87 sites in the US, UK, Spain, France and Belgium. 5,197 participants were randomised in a 2:1 ratio to receive a single IM dose of either 300mg of AZD7442 (n = 3,460) or saline placebo (n = 1,737), administered in two separate, sequential IM injections.

The primary analysis reported on 20 August 2021 was based on 5,172 participants, with data cut-off 9 May 2021. The primary efficacy endpoint was the first case of any SARS-CoV-2 RT-PCR positive symptomatic illness occurring post dose prior to day 183.The six-month assessment was based on 4,991 participants, with data cut-off of 29 August 2021. Subjects will continue to be followed for 15 months. Participants who chose to leave the PROVENT trial at any point to get vaccinated were excluded from the primary and six-month efficacy analyses.

Participants were adults 18 years-old and over who would benefit from prevention with the LAAB, defined as having increased risk for inadequate response to active immunisation (predicted poor responders to vaccines or intolerant of vaccine) or having increased risk for SARS-CoV-2 infection, including those whose locations or circumstances put them at appreciable risk of exposure to the SARS-CoV-2 virus. Participants at the time of screening were unvaccinated and had a negative point-of-care SARS-CoV-2 serology test.

Approximately 43% of participants were 60 years and over. In addition, more than 75% had baseline co-morbidities and other characteristics that are associated with an increased risk for severe COVID-19 should they become infected, including those with immunosuppressive disease or taking immunosuppressive medications, diabetes, severe obesity or cardiac disease, chronic obstructive pulmonary disease, chronic kidney and chronic liver disease.

AstraZeneca is progressing with filings around the globe for potential emergency use authorisation or conditional approval of AZD7442 in both prophylaxis and treatment.

TACKLETACKLE is a Phase III, randomised, double-blind, placebo-controlled, multi-centre trial assessing the safety and efficacy of a single 600mg IM dose of AZD7442 compared to placebo for the outpatient treatment of COVID-19. 903 participants were randomised (1:1) to receive either AZD7442 (n = 452) or saline placebo (n = 451), administered in two separate, sequential IM injections. The primary analysis was reported on 11 October 2021.

Participants were adults 18 years-old and over who were non-hospitalised with mild-to-moderate COVID-19 and symptomatic for seven days or less. Participants had a documented laboratory-confirmed SARS-CoV-2 infection, as determined by a molecular test (antigen or nucleic acid) from any respiratory tract specimen (e.g. oropharyngeal, nasopharyngeal, or nasal swab or saliva) collected no more than three days prior to day one.

The primary efficacy endpoint was the composite of either severe COVID-19 or death from any cause through day 29. Subjects will continue to be followed for 15 months.

Approximately 13% of participants were 65 years and over. In addition, 90% had baseline co-morbidities and other characteristics that put them at high risk of progression to severe COVID-19, including cancer, diabetes, obesity, chronic lung disease or asthma, cardiovascular disease or immunosuppression.

AZD7442AZD7442 is a combination of two LAABs - tixagevimab (AZD8895) and cilgavimab (AZD1061) - derived from B-cells donated by convalescent patients after SARS-CoV-2 virus. Discovered by Vanderbilt University Medical Center andlicensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein7and were optimised by AstraZeneca with half-life extension and reduced Fc receptor and complement C1q binding. The half-life extension more than triples the durability of its action compared to conventional antibodies and could afford up to 12 months of protection from COVID-19 following a single administration8-10; data from the Phase III PROVENT trial show protection lasting at least six months, with the Phase I trial showing high neutralising antibody titres for at least nine months.11The reduced Fc receptor binding aims to minimise the risk of antibody-dependent enhancement of disease - a phenomenon in which virus-specific antibodies promote, rather than inhibit, infection and/or disease.12

AZD7442 is also being studied as a potential treatment for hospitalised COVID-19 patients as part of the National Institute of HealthsACTIV-3 trialand in an additional collaborator hospitalisation treatment trial.

AZD7442 is being developed with support from the US Government, including federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, under Contract No. W911QY-21-9-0001.

In preclinical experiments, data show the LAABs were able to block the binding of the SARS-CoV-2 virus to host cells and protect against infection in cell and animal models of disease.13Additionalin vitrofindings demonstrate AZD7442 neutralises recent emergent SARS-CoV-2 viral variants, including the Delta and Mu variants.14

Under the terms of the licensing agreement with Vanderbilt, AstraZeneca will pay single-digit royalties on future net sales.

AstraZenecaAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

ContactsFor details on how to contact the Investor Relations Team, please clickhere. For Media contacts, clickhere.

References1. Oliver, S MD. Data and clinical considerations for additional doses in immunocompromised people. ACIP Meeting July 22, 2021. Available at:https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/07-COVID-Oliver-508.pdf. [Last accessed: November 2021].2. Centers for Disease Control and Prevention. Altered immunocompetence. General best practice guideline for immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices. [Online]. Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html. [Last accessed: November 2021].3. Boyarsky BJ, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA 2021; 325 (17):1784-1786.4. Rabinowich L, et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients, Journal of Hepatology (2021), doi: https://doi.org/10.1016/ j.jhep.2021.04.020.5. Deepak P, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv [Preprint]. 2021 Apr 9:2021.04.05.21254656. doi: 10.1101/2021.04.05.21254656. PMID: 33851176; PMCID: PMC8043473.6. Simon D, et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2021 May 6: annrheumdis-2021-220461. doi: 10.1136/annrheumdis-2021-220461. Epub ahead of print. PMID: 33958324.7. Dong J, et al. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv. 2021; doi: 10.1101/2021.01.27.428529.8. Robbie GJ, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013; 57 (12): 6147-53.9. Griffin MP, et al. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother. 2017; 61(3): e01714-16.10. Domachowske JB, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J. 2018; 37(9): 886-892.11. Loo Y-M, et al. AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans. medRxiv. Cold Spring Harbor Laboratory Press; 2021 [preprint] Available from: https://www.medrxiv.org/content/10.1101/2021.08.30.21262666v1.12. van Erp EA, et al. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019; 10: 548.13. Zost SJ, et al.Potently neutralizing and protective human antibodies against SARS-CoV 2.Nature. 2020; 584: 443449.14. ACTIV. National Center for Advancing Translational Sciences OpenData Portal. SARS-CoV-2 Variants & Therapeutics, All Variants Reported in vitro Therapeutic Activity. Available at: https://opendata.ncats.nih.gov/variant/activity [Last accessed: November 2021].

SOURCE: AstraZeneca

See the original post here:

New analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirm robust efficacy and long-term prevention | Antibodies | News...

nitpicker / Shutterstock

The U.S. Food and Drug Administration (FDA) has extended its review ofBristol Myers Squibb'sNew Drug Application (NDA) for the proposed heart drug mavacamten to allow more time to evaluate its product information.

Theextension to April 28, 2022, will give the regulator sufficient time to look into the drug for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The FDA will especially evaluate updates to the proposed Risk Evaluation Mitigation Strategy (REMS), which was included in the initial application.

Mavacamten is a candidate cardiac myosin inhibitor for patients diagnosed with oHCM. The company got ahold of mavacamten in November last year, following its $13.1 billionacquisition of MyoKardia. The NDA follows positive results from thePhase III EXPLORER-HCM study, which demonstrated an improvement in health status in patients after 30 weeks compared to those who took a placebo.

Outcomes were measured using the 23-item Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS), where 36% exhibited at least five points of change versus the 15% from the placebo group. The questions evaluated symptoms, social and physical function, and quality of life.

The primary endpoint for the trial was a composite functional analysis designed to assess mavacamten's effect on symptoms and function. The secondary endpoints were baseline changes at week 30 in pVO2, postexercise LVOT gradient, number of patients reporting improvement in at least one NYHA class, and patient reported outcomes. Other endpoints included week 30 baseline changes in circulating biomarkers, accelerometry, echocardiographic indices, and cardiac rhythm patterns.

"We are confident in the profile of mavacamten. This first-in-class cardiac myosin inhibitor demonstrated clinically meaningful improvements in symptoms, functional status, and quality of life in symptomatic oHCM patients in the pivotal EXPLORER-HCM trial. We look forward to continuing to work closely with theFDAto bring this important medicine to patients," said Samit Hirawat, M.D., the executive vice president and chief medical officer for global drug development for Bristol Myers Squibb, in a statement.

HCM is a chronic, progressive disease characterized by an excessive contraction of the heart muscle and reduced ability of the left ventricle to fill. It affects one in every 500 persons and can lead to cardiac dysfunction and other debilitating symptoms.

There are around 160,000 to 200,000 people diagnosed with the disease in the U.S. and the E.U., and there are no existing effective treatment options beyond providing relief for symptoms. HCM is also not always diagnosed, with only 25% of those with obstructive HCM and only 10% of those with non-obstructive HCM receiving a proper diagnosis.

The FDA has, so far, not requested any other documentation or studies to support its review extension.

Read the rest here:

New Mavacamten PDUFA Date Will Allow Further Risk Mitigation Review - BioSpace

Figure 1 Illustration of the location of drill hole P21-2331

Illustration of the location of drill hole P21-2331 in relation to last years drilling from drill pads Day-1 through Day-3. Planned underground development is shown in blue. Additional 2021 drill holes with assays pending from pad Day-4 are shown in dark green.

VANCOUVER, British Columbia, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF) (Ascot or the Company) is pleased to announce additional assay results from exploration drill holes from the 2021 drill program at the Companys Premier Gold Project (PGP). This release summarizes assays from the first drill hole at the Day Zone near the Big Missouri deposit and the balance of drill results from near the Premier deposit. Importantly, the new drill hole at the Day Zone has expanded mineralization approximately 400 metres to the south.

Highlights from the drill results include:

4.13 g/t Au and 3.5 g/t Ag over 2.46m from 291m depth in hole P21-2331, including 7.73 g/t Au and 4.1 g/t Ag over 0.96m at the Day Zone

17.05 g/t Au and 43 g/t Ag over 0.70m from 51m depth in hole P21-2323 in the area west of the Premier deposit

This release summarizes the results from ten surface drill holes west of the Premier deposit and one drill hole south of the Day Zone, for a total of 2,795m completed from four drill pads. As the winter season and snow accumulation has begun at site, drilling activities have wrapped up for the 2021 season. A total of 18,074 metres were drilled from surface. The 2021 drill program originally planned for 25,000 metres however permit delays restricted the start of underground drilling. Assay results for a total of 57 holes and 10,875 metres of drilling are still pending from the Woodbine target, the Day Zone, the Big Missouri deposit, and the Sebakwe target.

Derek White, President and CEO of Ascot commented, Since its initial discovery last year and through very modest amounts of additional drilling, the Day Zone has quickly evolved into one of our most prospective targets for potential resource growth near planned development. This is especially important for our strategy to increase mine life given the Day Zones proximity to the Big Missouri and Silver Coin deposits, which will be exploited in the early years of our mine plan. The 400-metre step-out hole to the south of the Day Zone highlights the size potential of this area, and we eagerly await assay results from an additional 7 holes drilled from the same pad. Assay results have taken much longer to process this year. We are looking forward to assays from both Big Missouri and Sebakwe, where visible gold was observed in drill core. As the Company continues to work with provincial permitting regulators, we look forward to getting final permits to progress development and underground drilling.

Story continues

Day Zone Target

The Day Zone, initially discovered in 2020 (see News Releases dated September 14, 2020, November 19, 2020, and January 18, 2021), is located on the western side of the Big Missouri Ridge, approximately 5 kilometres north of the Premier mill. Given the high-grade intercepts encountered in this area and its proximity to Big Missouri the first deposit to be exploited in the Companys mine plan the Day Zone is one of the most compelling targets for resource growth and potential mine life extension. The Day Zone is located just 300m west of reserve stopes at Big Missouri, and mineralization remains open to the north and south.

The first assay results from the Day Zone drilling program in 2021 come from a 400m southern step-out hole. Hole P21-2331 intercepted 4.13 g/t Au and 3.5 g/t Ag over 2.46m starting at a depth of 291m. Gold mineralization was intercepted at four different elevations that roughly correspond to known elevations of mineralization elsewhere at Big Missouri. The new drill hole is exploring an area of sparse geological information very close to the planned development drift from the Big Missouri deposit to the Silver Coin deposit. Additional drill holes from the same pad have been completed in order to establish the orientation of mineralization in this area (see Figure 1). Assays from these holes are pending and will be reported as they become available. The 400m of strike extent between hole P21-2331 and the Day Zone drill holes reported last year will be investigated in order to establish continuity of mineralization. The mineralization at the Day Zone has now been intercepted over a combined strike length of 550m and remains open to the north and to the south.

Figure 1 Illustration of the location of drill hole P21-2331 in relation to last years drilling from drill pads Day-1 through Day-3. Planned underground development is shown in blue. Additional 2021 drill holes with assays pending from pad Day-4 are shown in dark green.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1aff1a4a-94b7-45c5-ad32-d790616e5d5d

Table 1 Day Zone drill results

Hole #

Azimuth/dip

From(m)

To(m)

Width(m)

Au(g/t)

Ag(g/t)

P21-2331

270/-62

42.53

43.98

1.45

1.49

1.8

and

140.95

141.95

1.00

0.99

0.8

and

291.15

293.61

2.46

4.13

3.5

incl.

291.15

292.11

0.96

7.73

4.1

and

354.15

355.12

0.97

1.55

1.1

Note: The orientation of mineralization in this area is not sufficiently well understood to predict true width.

Premier Deposit Drilling

Earlier in the 2021 drill season, Ascot started surface drilling at lower elevations in the area west of the Premier deposit and near the mill building (see News Releases dated July 8, 2021 and August 9, 2021). Following up on the previously reported 50 metre step-out hole to the west of the existing resource at Northern Light which intercepted 21.13 g/t Au over 7.0m in hole P21-2320, a further ten holes totaling 2,404m were drilled along the implied extension of that limb.

The new drill holes were completed in an area with no previous drilling, targeting the projected extension of the Northern Light Zone at Premier. One additional high-grade intercept was encountered in hole P21-2323 that intercepted 17.05 g/t Au and 43 g/t Ag over 0.70m at the edge of a Tertiary dyke in the overlying Betty Creek formation.

Drill holes 2321, 2322, 2323 and 2324 intercepted sulfide mineralization in quartz breccia with highly anomalous gold values at roughly the expected depth without duplicating the spectacular results from drill hole 2320 a little further east. The next three drill holes did not return any significant results while drill holes 2328 and 2330 intercepted anomalous gold again. Both holes were drilled at a very steep dip and the results suggest that the mineralization may trend further to the north rather than the west as anticipated. This area of the deposit is concealed by younger volcanic cover and geological information is obtained exclusively from drill holes. Additional work in the future will be designed to establish the correct trace of the main trend of mineralization and its potential connection to the intercepts further west reported earlier in the year. The hydrothermal system appears to extend to the west of the established resource areas offering exciting potential for additional discoveries very close to the mine infrastructure.

Table 2 Premier deposit drill results

Hole #

Azimuth/dip

From(m)

To(m)

Width(m)

Au(g/t)

Ag(g/t)

P21-2321

190/-50

184.55

185.60

1.05

2.36

23.3

P21-2322

190/-65

152.00

153.00

1.00

0.71

11.2

P21-2323

190/-70

51.05

51.75

0.70

17.05

43.3

and

146.75

147.75

1.00

0.62

22.5

P21-2324

225/-60

156.10

158.00

1.90

0.21

2.1

View post:

Ascot Expands Day Zone Mineralization 400 Metres to the South With Step-Out Drill Hole - Yahoo Finance

In the News

Getting the big picture of biodiversityScience, 11/18/21Quoted: Volker Radeloff, Forest and Wildlife Ecology

In Real Life: WinesconsinNewsy via YouTube, 11/15/21Interviewed: Amaya Atucha, HorticultureFilming location: West Madison Agricultural Research Station

Inside the Bitter Debate Over How to Manage Wolves in WisconsinMilwaukee Magazine, 11/18/21Quoted: Tim Van Deelen, Forest and Wildlife Ecology

Wisconsins deer population is at a critical highWisconsin Public Radio, 11/19/21Quoted: Mike Samuel, Emeritus, Forest and Wildlife EcologyQuoted: Tom Hauge, Alumnus, Forest and Wildlife Ecology

With SARS-CoV-2 spreading in deer, state health officials urge extra precautions while huntingWisconsin Public Radio, 11/17/21Quoted: Tim Van Deelen, Forest and Wildlife Ecology

UW Extension names regional educators for dairy, cropsThe Chronotype, 11/15/21Mentioned: Ryan Sterry, Alumnus, Animal and Dairy Sciences

Keep Venison Safe This SeasonMid-West Farm Report, 11/15/21Quoted: Jeff Sindelar, Animal and Dairy Sciences

USDA announces $20.2M for dairy business innovationWisconsin State Farmer, 11/15/21Quoted: John Lucey, Food ScienceMentioned: Center for Dairy Research

Of Interest

DNR scraps groundwater protection effort; rulemaking process blamedWisconsin State Journal, 11/19/21

Flooding, pandemic, building closure: Disruptions take a toll on UW chemistry departmentWisconsin State Journal, 11/16/21

Graduate workers blast UW-Madison for paltry pay raisesThe Capital Times, 11/16/21

Torontos deep lake water cooling (DLWC) is the worlds largest. Heres how it works.Washington Post, 11/5/21

CALS in the Newsis a weekly selection of media stories quoting or mentioning CALS faculty, staff, students, alumni, research and programs. Other stories of interest to the UWMadison community and those in the fields of agriculture and the life sciences are also included. This list is produced by CALS External Relations. Read more about our mission and methodology for curating this list.

See original here:

CALS in the News for the Week of November 13 19 eCALS - wisc.edu

Stem cells are invaluable to your continued health and vitality. This is because stem cells can transform into other kinds of cells when your body needs them, a process called differentiation. Stem cells can also create more copies of themselves, which is called self-renewal. Both of these properties are essential to tissue rejuvenation.

A healthy balance between these two actions promotes healthy tissue maintenance, growth, and longevity. But aging can cause stem cells to no longer function optimallyoften losing the ability to self-renew, or differentiate into other cells, or both.1 Weve created GEROPROTECT Stem Cell to help maintain youthful, healthy stem cell function.

Nutrients to encourage balanced stem cell health

GEROPROTECT Stem Cell promotes youthful, healthy stem cell function and encourages balanced stem cell differentiation and self-renewal. It does so with nutrients that promote the cellular pathways that help maintain youthful stem cell behavior: a healthy, functional protein pool, DNA health, AMPK signaling, and more.

These compounds were identified in partnership with Insilico Medicine, Inc., a machine learning company whose proprietary algorithm is based on 21st Century artificial intelligence computing techniques.

Presveratrol proprietary blend

Preservatrol is a proprietary blend of resveratrol and piceatannol, an extract of passion fruit. In vivo and in vitro studies indicate that piceatannol promotes stem cell differentiation as well as proteostasisthe quality control network that helps ensure the integrity of proteins within our cells.2-4

Resveratrol is a phytonutrient with well-known benefits for longevity and health. In vivo and in vitro studies indicate that resveratrol has beneficial effects on stem cell health.6,7 Additionally, the combination of resveratrol and piceatannol promotes DNA health as well as encourages the bodys natural pathways for managing senescent stem cells.8

Livinol kokum extract (garcinol)

Garcinol is a compound derived from the kokum (garcinia indica) fruit. In vitro studies indicate that garcinol helps to positively regulate healthy stem cell self-renewal and differentiation.9-11 Garcinol inhibits an enzyme called histone acetyltransferase, or HAT. This enzyme is part of a process called histone acetylationone of the main causes of stem cell aging and loss of function. By inhibiting this enzyme, garcinol helps restore youthful stem cell function and longevity.

Combining cell support

GEROPROTECT Stem Cell can be taken by itself, with our other GEROPROTECT products or paired with our innovative Senolytic Activator formula for enhanced youthful cellular health support.

Go here to read the rest:

GeroProtect Stem Cell, 60 vegetarian capsules - Life Extension

Cryogenically frozen dead people are held preserved in a clinic at Scottsdale, Arizona in the hope that maybe someday science would be advanced enough to bring them back to life. This unique cryonics clinic is run by Alcor Life Extension Foundation, and surprisingly, many people, including some famous personalities like PayPal co-founder Peter Theil, are actually spending hundreds of thousands of dollars to have their bodies preserved here after death.

The idea of waking up in the future sounds like a great plot for a sci-fi movie or a novel but through cryonics, organizations like Alcor are trying to do the same in reality. Max Moore, a futurist and the former CEO of Alcor,believes that people can be rescued from death. Our view is that when we call someone dead it's a bit of an arbitrary line. In fact they are in need of a rescue, he said in an interview. Whats perhaps more surprising is that Alcor is not the only cryonics clinic preserving dead bodies for revival in the future.

Cryonics isthelow-temperature preservation ofa newly-dead body or the severed head of an individual. To compare, freezing a dead body is called cryonics, the science of super-low temperatures is called cryogenics. In cryonics, the body is stored at temperatures below 130 degrees Celsius in the hope thatsome advanced technology or nanotechnology would be able to resurrect the person in the future. To protect the body parts from any damage during the freezing and storage, cryonics practitioners use cryo-protectants and cryo-preservation, which can be considered similar techniques to those used to keep the body organs of an organ donor from decaying after their death.

For those who have signed up for cryonics, an emergency cryonics response team takes control of the body after they are declared medically dead. Within hours of death, they pack the body in ice andensure that oxygen and blood supply to the brain. The team injects heparin into the body so that your blood does not coagulate while they transport it to a cryonics facility from the place of death.

At the cryonics facility, the body is put on a machine that circulates the blood and maintains oxygenation, similar to a heart-lung bypass machine. A vitrification solution is pumped in. This is a cryo-protectant and it works like antifreeze to keep the bodys tissues from turning to ice crystals during freezing. This is needed because, when your body is frozen, the ice crystals can rupture cells and cause damage to tissues and organs.

The body is then slowly cooled to around -320 (-195C) using a liquid nitrogen vapor chamber; once its cold enough, the body is transferred to a tank of liquid nitrogen where it will bestored at around -320.8 (-196C) in an inverted position. The aim here is to prevent any damage from occurring in the brain even if there is a leak. During the time the body is stored in liquid nitrogen containers, cryonicists argue that the cells are believed to remain in a dormant state.

Though famous personalities like Paris Hilton, Peter Thiel, Steve Aoki, Robert Miller, and many others are reported to look forward to having their bodies cryopreserved, it is a controversial topic among the scientific community. People who advocate cryonics consider the technique a way to overcome death, but on the other side, there are scientists who claim that cryonics is nothing but a pseudoscience, giving people false hope in the name of technology.

According to Max Moore, Alcor is not a hope monger. Scientific evidence was no more a prerequisite than hope for believing in an afterlife. For members ... that's enough to pay for, said Moore to NBC News.

Dennis Kowalski, president of the Cryogenics Institute in Michigan, believes that cryonics may sound like sci-fi but it is ultimately an optimistic technology. In favor of cryonics, he says, you have nothing to lose, everything to gain other than some life insurance money, and for me, it's worth it. Kowalski himself,his wife, and his children have also enrolled to undergo cryopreservation after their deaths.

The different points of view that researchers and cryopreservation experts have for cryonics can perhaps be understood through examining a court case that emerged in the UK.

In November 2016, a 14-year UK girl referred to as JS passed away due to a rare form of cancer. Before dying, she left a note saying that her last wish is to have her body cryopreserved so that in the future she might be revived. The note read, in part,I dont want to be buried underground. I want to live and live longer and I think that in the future they might find a cure for my cancer and wake me up. I want to have this chance. This is my wish.

The mother of JS wanted to fulfill her daughters last wish, but her estranged father opposed it. Eventually, JS's last wish led not only to a legal dispute between her parents, but also divided the scientific community in the UK as to the speculative nature of cryonics.

Responding to the case, cryobiologist Ramon Risco told The Guardian that while cryonics is currently an unbelievable concept, just like "test-tube babies" or space travel once was, it should not be considered an impossibility. He believesthat in five to 10 years experts will likely have progressed enough to revive small mammals after preservations in liquid nitrogen. It is very risky to say that anything is impossible in science or technology in the 21st century people who use the word impossible are very brave, he said. If you are looking for the truth, why would you put barriers up?

Risco also argued that many scientists are against cryonics because supporting this idea could endanger their careers. He said, There is an enormous stigma bias to the conversation about cryonics among scientists. For scientists who would like to discuss it open-mindedly, it tends to significantly hurt their career in fact, can potentially even get them kicked out of their scientific societies.

Clive Coen, a leading neuroscience professor from Kings College, London was one of those who opposed the high courts decision to allow the cryopreservation of JS. Professor Coen argued, ethically its very complicated. The trade-off is that she got the comfort, but others may now be duped." He even demanded a complete ban on cryonics marketing.

Renowned cosmologist Martin Rees also raised concerns on the practicality and ethical issues pertaining to cryonics. He suggested that cryonics enthusiasts cannot be believed, because the claims made by them are ridiculous. Even many supporters and cryonics experts also admitthat there is a chance some companies might take advantage of peoples vulnerability in the name of cryopreservation.

For now, there is no scientific evidence that completely approves or explains the possibility of a new life in the future through cryonics. As far as legal issues are concerned, U.S. law does not treat cryopreservation and organ donation as two different things. As per the Uniform Anatomical Gift Act (UAGA), practices like cryonics are similar to a scientific experiment, for which people willingly donate their bodies and organs.

This also implies that organizations such as the Alcor Life Extension Foundation and the Cryonics Institute cannot be held responsible if they are unable to revive clients in the future after undergoing cryopreservation.

Instead of being buried or cremated after death, thousands of peoplefrom different parts of the globe have signed up for cryopreservation. However, this is not the only surprising fact related to cryonics.

On January 12, 1967, American psychologist Dr. James Bedford underwent cryopreservation soon after his death. He was the first personin the world who decided to do so, and his frozen body is still resting at Alcor Life Extension Foundation in Arizona.

Anyone can cryopreserve their entire body at Alcor for $200,000, or just the head for $80,000. Surprisingly, the Cryonics Institute only charges $28,000 to cryopreserve a human body. When asked about this huge price gap, a representative from Alcor revealed that a major part of their fee is spent to support their patient care trust fund which funds the maintenance of the facilities until such time as revival is possible.

American baseball player Ted Williams was also cryopreserved at Alcor. The idea of cryonics has been quite popular among celebrities; for example, DJ Steve Aoki has not only signed up for cryonics but also endorsed Alcor.

The number of bodies stored at Alcor has grown at a rate of around 8% a year. The oldest stored body is a 101 years old woman and the youngest is just 2. One in four of Alcor's customers live in theSan Francisco Bay Area.

KrioRus, a cryonics company in Russia also allows its clients to cryopreserve their pets. Recently, the founder of Krio Rus, Danila Medvedev, accused her ex-wife Valeria Udalova of raiding the companys cryonic storage facility and stealing liquid nitrogen containers containing frozen dead bodies.

Cryonics has been a controversial subject. There is a possibility that, except for the frozen dead bodies, no one might ever be able to witness their revival, or perhaps, they may never come back to life.

Read the original here:

Cryonics Clinics: Where People Sleep and Wake Up in the Future - Interesting Engineering

Critically Acclaimed #1 Podcast "We Can Do Hard Things" Expanded to Twice Weekly

NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Leading premium podcast studio Cadence13, an Audacy company, today announced that it has signed a multi-year contract extension with #1 New York Times bestselling author, activist, and thought leader Glennon Doyle for her critically acclaimed #1 podcast We Can Do Hard Things.

Cadence13 Signs Multi-Year Contract Extension with Globally Renowned Thought Leader, New York Times Bestselling Author, and Activist Glennon Doyle

On the show, Doyle, along with her sister Amanda Doyle and her wife Abby Wambach, shares stories of her life and explores topics including love, relationships, parenting, mental health, recovery, boundaries, redefining family, sex, and more.

Soon after its launch in May 2021, Cadence13 expanded We Can Do Hard Things from a weekly to a twice-weekly show, with new episodes dropping Tuesdays and Thursdays.

The new agreement includes bonus episodes, events, and an early drop of select episodes of We Can Do Hard Things on the Audacy app.

"On 'We Can Do Hard Things,' my wife Abby, my sister Amanda, and I do the only thing I've found that has ever made life easier: We drop the fake and talk honestly about the hard. Each week we bring our hard to you and you bring your hard to us -- we help each other carry it, so we can all live a little bit lighter and braver, more free and less alone," said Glennon Doyle, host of We Can Do Hard Things. "Cadence13 has been a dream partner to help bring our vision for this community to life. I am grateful for the team's steadfast support and advocacy of our podcast, and I am thrilled to have Cadence13 by our side as we continue to have hard, important, intimate, and connecting conversations with our community in the years ahead."

"From the first episode of 'We Can Do Hard Things,' Glennon's innumerable talents and instincts--including her raw honesty and natural ability to bond with listeners over shared vulnerabilities and the things that make us human, along with her extraordinary sense of humor--immediately catapulted her and the show not only to the top spot on the Apple Podcast charts, but into the hearts of millions around the world," said Chris Corcoran, Chief Content Officer, Cadence13. "We're incredibly proud of the show, honored to count Glennon as a member of the Cadence13 family, and look forward to a long and successful partnership."

Story continues

Hailed as the "patron saint of female empowerment" by People magazine, Doyle has amassed a fervent following with a series of transformative booksthe #1 New York Times bestseller Untamed, a Reese's Book Club selection which has sold over two million copies and Audible's most-listened to audiobook all of 2020; the #1 New York Times bestseller Love Warrior, an Oprah's Book Club selection, and Carry On, Warrior. Adele credits Doyle's writing with changing her life, Oprah named her one of the world's "awakened leaders who are using their voices and talent to elevate humanity," and over 3M people follow her on social media. She is the founder and president of Together Rising, an all-women led nonprofit organization that has revolutionized grassroots philanthropyraising over $30 million for women, families, and children in crisis.

Follow Glennon on Twitter @GlennonDoyle, Instagram @GlennonDoyle, and Facebook at Glennon Doyle. Learn more at UntamedBook.com and GlennonDoyle.com.

Download the cover art for We Can Do Hard Things and Glennon Doyle's photo (credit: Melissa Lyttle) here.

For more information, please visit WeCanDoHardThingsPodcast.com.

Glennon Doyle is repped by WME.

About Glennon Doyle: Glennon Doyle is a thought leader, activist, and the author of the #1 New York Times bestseller Untamed, a Reese's Book Club selection, which has sold over two million copies. She is also the author of the #1 New York Times bestseller Love Warrior, an Oprah's Book Club selection, and Carry On, Warrior. Glennon is the founder and president of Together Rising, an all-women-led nonprofit organization that has revolutionized grassroots giving raising over $30 million for women, families, and children in crisis. She lives in California with her wife and three children.

About Cadence13:Cadence13, an Audacy company, is a leading podcast studio dedicated to premium storytelling and production and was named one of Fast Company's "World's Most Innovative Companies for 2019." Cadence13 is the home of C13Features, the pioneering studio focused on creating a wide-ranging slate of feature-length podcast movies, the Peabody Award-nominated C13Originals documentary studio, and Ramble, a podcast network of some of the most influential digital stars in the world. Our roster of critically-acclaimed shows and personalities reflects the diverse conversations and interests happening in the world, led by a collection of voices that include Lili Anolik, Carmelo Anthony, Pete Carroll, Emma Chamberlain, Darren Criss, Remi Cruz, Charli and Dixie D'Amelio, Glennon Doyle, Kevin Durant, Elle Fanning, Jon Favreau, Dr. Eddie S. Glaude Jr., Gigi Gorgeous, Mark-Paul Gosselaar, Vanessa Grigoriadis, Justine Harman, Shawn Levy, Demi Lovato, Este Haim, Andrew Jenks, Tony Kornheiser, Payne Lindsey, Elise Loehnen, Michael Lombardi, Karina Longworth, Jon Lovett, Kate Mara, Alisha Marie, CJ McCollum, Jon Meacham, James Andrew Miller, Gwyneth Paltrow, Ellen Pompeo, JJ Redick, Doc Rivers, Rhett and Link, Adam Scott, Kiernan Shipka, Tommy Vietor, Andrew Yang, and many more. These storytellers represent both established and emerging personalities across sports, business, tech, politics, entertainment and news. Cadence13 has a broad range of programming partners including: American Public Media, Comments by Celebs, Crooked Media, goop, HISTORY, Meredith, Mythical Entertainment, OBB Sound, PushBlack, Ramble, SB Projects, Seven Bucks Productions, Tenderfoot TV, theSkimm, The Try Guys, TNT, Unsolved Mysteries, Up and Vanished, Vanity Fair, Who? Weekly, and Yoga Girl, among others. Cadence13 is headquartered in New York, with offices in Los Angeles. Follow @Cadence13_, @C13Originals and @C13Featureson Twitter and @Cadence13, @C13Originals and @C13Features on Instagram.

About Audacy: Audacy, Inc. (NYSE: AUD) is a scaled, multi-platform audio content and entertainment company with the country's best radio broadcasting group, a leader in virtually every segment of audio, and America's #1 creator of original, premium audio. Audacy engages over 170 million consumers each month, bringing people together around the news, sports, podcasts and music that matter to them. Learn more at http://www.audacyinc.com, Facebook (Audacy Corp) and Twitter (@AudacyCorp).

Contact:Hillary SchupfVP, Publicity |Cadence13917.828.4280hillary@cadence13.com

(PRNewsfoto/Cadence13)

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/cadence13-signs-multi-year-contract-extension-with-globally-renowned-thought-leader-new-york-times-bestselling-author-and-activist-glennon-doyle-301419686.html

SOURCE Cadence13

Read this article:

Cadence13 Signs Multi-Year Contract Extension with Globally Renowned Thought Leader, New York Times Bestselling Author, and Activist Glennon Doyle -...

ONCE upon a time before Instagram and Facebook took over the world, there was MySpace.

And the first friend users ever had was its founder Tom Anderson.

1

Tom Anderson, who was known as "Tom from MySpace", "MySpace Tom" or "My friend, Tom", retired at 40 and is now a travel photographer.

He posts on social media under themyspacetom, and his Instagram bio reads: "Former 1st friend, Surfing, travel/photos, architecture-design, DogDad, SpaceX & CRISPR Investr, Life Extension."

The photographer, 50, who now lives in Hawaii, obviously travels extensively as he posts numerous pictures on his Twitter and Instagram profiles.

Often they are taken from exotic destinations such as Thailand, Bhutan and the Maldives

As of November 2021, he has an impressive 647,000 fans admiring his impressive photography.

According to Influencive in 2017, Tom said about his new work: "My passion for photography is what keeps me traveling.

"I have multiple homes in multiple cities, but Im not satisfied just staying where Im comfortable. I want to keep creating.

I wasnt taking photography all that seriously, I just wanted to document a wild scene.

"But when I loaded the photos on to my computer, I was hooked. I knew I wanted to capture more scenes around the world.

After retiring in 2009, he started building and designing houses.

Anderson collaborated with Chris DeWolfe on MySpace in 2003.

Now 55, DeWolfe quit being the CEO of MySpace in 2009.

He has been the CEO of Jam City, a video game developer, since he co-founded it in 2010.

Jam City has worked with Disney and Warner Bros, and in 2018 launched Harry Potter: Hogwarts Mystery, which became the fastest game to hit $100million in revenue in Jam Citys history

Anderson was replaced as president in April 2009 by MySpaces new owner News Corp.

By 2010, he was no longer the default friend, and was replaced by a profile called "Today On MySpace", or "T.O.M."

We pay for your stories!

Do you have a story for The US Sun team?

See the original post:

Where is Tom from MySpace now?... - The Sun

VANCOUVER, British Columbia / Nov 04, 2021 / Business Wire / Capstone Mining Corp. (Capstone or the Company) (TSX:CS) today announced that it has received final approvals from the US Forest Service for a new mine plan of operations (the Plan) for the Pinto Valley Mine (Pinto Valley). The Plan, approved by the Tonto National Forest (TNF), extends Pinto Valleys life of mine to the year 2039. The mine life extension is expected to produce 2.5 billion pounds of copper and will preserve approximately 700 jobs in Arizonas Gila County, contributing to the areas economic activities over the next two decades.

TNFs approval process included a detailed evaluation of technical data provided by Pinto Valley Mining Corp. and a stakeholder consultation process. The plan allows for Pinto Valleys continued operation and includes additional environmental controls, as well as monitoring and mitigation measures to address potential environmental impacts from the mines operations.

Darren Pylot, Capstones President & CEO commented, I would like to congratulate our Pinto Valley team on this significant permitting achievement which will translate into continued benefits for the community of Globe-Miami for decades to come. We recently completed a $31 million optimization project which has increased productivity, decreased costs, and built a more resilient operation.

This is truly a historic day for Capstone Mining and our flagship Pinto Valley Mine, said Brad Mercer, SVP & COO. Mr. Mercer added, This approval took more than 5 years to obtain and we thank the US Forest Service employees who helped keep this project on track.

ABOUT CAPSTONE MINING CORP.

Capstone Mining Corp. is a Canadian base metals mining company, focused on copper. We are committed to the responsible development of our assets and the environments in which we operate. Our two producing mines are the Pinto Valley copper mine located in Arizona, US and the Cozamin copper-silver mine in Zacatecas State, Mexico. In addition, Capstone owns 100% of Santo Domingo, a large scale, fully permitted, copper-iron-gold project in Region III, Chile, as well as a portfolio of exploration properties. Capstone's strategy is to focus on the optimization of operations and assets in politically stable, mining-friendly regions, centred in the Americas. Our headquarters are in Vancouver, Canada and we are listed on the Toronto Stock Exchange (TSX) under the symbol CS.

Further information is available at http://www.capstonemining.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document may contain forward-looking information within the meaning of Canadian securities legislation and forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 (collectively, forward-looking statements). These forward-looking statements are made as of the date of this document and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required under applicable securities legislation.

Forward-looking statements relate to future events or future performance and reflect our expectations or beliefs regarding future events and the impacts of the ongoing and evolving COVID-19 pandemic. Forward-looking statements include, but are not limited to statements with respect to expected production at Pinto Valley from extension and the preservation of jobs in Arizonas Gila County, the estimation of Mineral Resources and Mineral Reserves, the expected timing, operations and success of the underground paste backfill system study and tailings filtration project at Cozamin, the outcome and timing of the PV4 study, the timing and success of our use of the Jetti Technology, the successful execution of a port services agreement with Puerto Ventanas and/or rail agreement with Sigdo Koppers rail business, the success of our strategic process for the Santo Domingo project, the expected reduction in capital requirements for the Santo Domingo project, the timing and success of the Cobalt Study for Santo Domingo, the success of the PV3 Optimization project, the realization of Mineral Reserve estimates, the timing and amount of estimated future production, costs of production and capital expenditures and reclamation, the success of our mining operations, the success of mineral exploration, the estimations for potential quantities and grade of inferred resources and exploration targets, Capstones ability to fund future exploration activities, Capstones ability to finance the Santo Domingo project, Capstone's ability to find a strategic partner, environmental risks, unanticipated reclamation expenses and title disputes. The potential effects of the COVID-19 pandemic on our business and operations are unknown at this time, including Capstones ability to manage challenges and restrictions arising from COVID-19 in the communities in which Capstone operates and our ability to continue to safely operate and to safely return our business to normal operations. The impact of COVID-19 to Capstone is dependent on a number of factors outside of our control and knowledge, including the effectiveness of the measures taken by public health and governmental authorities to combat the spread of the disease, global economic uncertainties and outlook due to the disease, and the evolving restrictions relating to mining activities and to travel in certain jurisdictions in which we operate.

In certain cases, forward-looking statements can be identified by the use of words such as anticipates, approximately, believes, budget, estimates, expects, forecasts, guidance, intends, plans, scheduled, target, or variations of such words and phrases, or statements that certain actions, events or results be achieved, could, may, might, occur, should, will be taken or would or the negative of these terms or comparable terminology. In this document certain forward-looking statements are identified by words including anticipated, expected, guidance and plan. By their very nature, forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, amongst others, risks related to inherent hazards associated with mining operations and closure of mining projects, future prices of copper and other metals, compliance with financial covenants, surety bonding, our ability to raise capital, Capstones ability to acquire properties for growth, counterparty risks associated with sales of our metals, use of financial derivative instruments and associated counterparty risks, foreign currency exchange rate fluctuations, market access restrictions or tariffs, changes in general economic conditions, availability of water, accuracy of Mineral Resource and Mineral Reserve estimates, operating in foreign jurisdictions with risk of changes to governmental regulation, compliance with governmental regulations, compliance with environmental laws and regulations, reliance on approvals, licenses and permits from governmental authorities and potential legal challenges to permit applications, contractual risks including but not limited to, our ability to meet the completion test requirements under the Cozamin Silver Stream Agreement with Wheaton Precious Metals, our ability to meet certain closing conditions under the Santo Domingo Gold Stream Agreement with Wheaton Precious Metals, acting as Indemnitor for Minto Exploration Ltd.s surety bond obligations post divestiture, impact of climate change and changes to climatic conditions at our Pinto Valley and Cozamin operations and Santo Domingo project, changes in regulatory requirements and policy related to climate change and greenhouse gas ("GHG") emissions, land reclamation and mine closure obligations, risks relating to widespread epidemics or pandemic outbreak including the COVID-19 pandemic; the impact of COVID-19 on our workforce, suppliers and other essential resources and what effect those impacts, if they occur, would have on our business, including our ability to access goods and supplies, the ability to transport our products and impacts on employee productivity, the risks in connection with the operations, cash flow and results of Capstone relating to the unknown duration and impact of the COVID-19 pandemic, uncertainties and risks related to the potential development of the Santo Domingo project, increased operating and capital costs, increased cost of reclamation, challenges to title to our mineral properties, increased taxes in jurisdictions the Company operates or is subject to tax, changes in tax regimes we are subject to and any changes in law or interpretation of law may be difficult to react to in an efficient manner, maintaining ongoing social license to operate, dependence on key management personnel, potential conflicts of interest involving our directors and officers, corruption and bribery, limitations inherent in our insurance coverage, labour relations, increasing energy prices, competition in the mining industry including but not limited to competition for skilled labour, risks associated with joint venture partners, our ability to integrate new acquisitions and new technology into our operations, cybersecurity threats, legal proceedings, the volatility of the price of the Common Shares, the uncertainty of maintaining a liquid trading market for the Common Shares, risks related to dilution to existing shareholders if stock options or other convertible securities are exercised, the history of Capstone with respect to not paying dividends and anticipation of not paying dividends in the foreseeable future, and sales of Common Shares by existing shareholders can reduce trading prices, and other risks of the mining industry as well as those factors detailed from time to time in the Companys interim and annual financial statements and MD&A of those statements and Annual Information Form, all of which are filed and available for review under the Companys profile on SEDAR at http://www.sedar.com. Although the Company has attempted to identify important factors that could cause our actual results, performance or achievements to differ materially from those described in our forward-looking statements, there may be other factors that cause our results, performance or achievements not to be as anticipated, estimated or intended. There can be no assurance that our forward-looking statements will prove to be accurate, as our actual results, performance or achievements could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on our forward-looking statements.

CAUTIONARY NOTE TO UNITED STATES INVESTORS REGARDING PRESENTATION OF MINERAL RESERVE AND MINERAL RESOURCE ESTIMATES

As a British Columbia corporation and a reporting issuer under Canadian securities laws, we are required to provide disclosure regarding our mineral properties in accordance with Canadian National Instrument 43-101 Standards of Disclosure for Mineral Projects (NI 43-101). NI 43-101 is a rule developed by the Canadian Securities Administrators that establishes standards for all public disclosure an issuer makes of scientific and technical information concerning mineral projects. In accordance with NI 43-101, we use the terms mineral reserves and resources as they are defined in accordance with the CIM Definition Standards on mineral reserves and resources (the CIM Definition Standards) adopted by the Canadian Institute of Mining, Metallurgy and Petroleum. In particular, the terms mineral reserve, proven mineral reserve, probable mineral reserve, mineral resource, measured mineral resource, indicated mineral resource and inferred mineral resource used in this news release and the documents incorporated by reference herein and therein, are Canadian mining terms defined in accordance with CIM Definition Standards. These definitions differ from the definitions in the disclosure requirements promulgated by the SEC. Accordingly, information contained in this news release and the documents incorporated by reference herein may not be comparable to similar information made public by U.S. companies reporting pursuant to SEC disclosure requirements.

United States investors are also cautioned that while the SEC will now recognize measured mineral resources, indicated mineral resources and inferred mineral resources, investors should not assume that any part or all of the mineralization in these categories will ever be converted into a higher category of mineral resources or into mineral reserves. Mineralization described using these terms has a greater amount of uncertainty as to their existence and feasibility than mineralization that has been characterized as reserves. Accordingly, investors are cautioned not to assume that any measured mineral resources, indicated mineral resources, or inferred mineral resources that we report are or will be economically or legally mineable. Further, inferred resources have a greater amount of uncertainty as to their existence and as to whether they can be mined legally or economically. Therefore, United States investors are also cautioned not to assume that all or any part of the inferred resources exist. In accordance with Canadian rules, estimates of inferred mineral resources cannot form the basis of feasibility or other economic studies, except in limited circumstances where permitted under NI 43-101.

NATIONAL INSTRUMENT 43-101 COMPLIANCE

Unless otherwise indicated, Capstone has prepared the technical information in this news release (Technical Information) based on information contained in the technical reports, Annual Information Form and news releases (collectively the Disclosure Documents) available under Capstone Mining Corp.s company profile on SEDAR at http://www.sedar.com. Each Disclosure Document was prepared by or under the supervision of a qualified person (a Qualified Person) as defined in National Instrument 43-101 Standards of Disclosure for Mineral Projects of the Canadian Securities Administrators (NI 43-101). Readers are encouraged to review the full text of the Disclosure Documents which qualifies the Technical Information. Readers are advised that Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability. The Disclosure Documents are each intended to be read as a whole, and sections should not be read or relied upon out of context. The Technical Information is subject to the assumptions and qualifications contained in the Disclosure Documents.

Disclosure Documents include the National Instrument 43-101 compliant technical reports titled "NI 43-101 Technical Report on the Cozamin Mine, Zacatecas, Mexico" effective October 23, 2020, Pinto Valley Mine Life Extension Phase 3 (PV3) Pre-Feasibility Study effective January 1, 2016 and Santo Domingo Project, Region III, Chile, NI 43-101 Technical Report effective February 19, 2020.

The disclosure of Scientific and Technical Information in this news release was reviewed and approved by Brad Mercer, P. Geol., Senior Vice President and Chief Operating Officer (technical information related to mineral exploration activities and to Mineral Resources at Cozamin), Clay Craig, P.Eng, Manager, Mining & Evaluations (technical information related to Mineral Reserves and Mineral Resources at Pinto Valley), Tucker Jensen, Superintendent Mine Operations, P.Eng (technical information related to Mineral Reserves at Cozamin) and Albert Garcia III, PE, Vice President, Projects (technical information related to project updates at Santo Domingo) all Qualified Persons under NI 43-101.

Read more:

Capstone's Pinto Valley Mine Receives New US Forest Service Mine Plan of Operations to Fully Permit Mine Life to 2039 - Junior Mining Network